hong-kong

2018 Speakers

 

Dr. Larry Zhang is currently the vice president of Novartis Group (China), responsible for Public Affairs and Corporate Responsibility. Larry has more than 20 years management experience in healthcare and bio-pharmaceutical industry in the US, Asia Pacific and China. Prior to the present role, Larry had been CEO of Sandoz Pharmaceutical (China), a Novartis Company, for more than 5 years, where he led the truly turnaround and fast growth. Larry has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the the US and Asia Pacific. Larry is member of Board of Directors of SwissCham Beijing. Larry holds his bachelor and master degrees in nuclear physics, Ph.D in political science and MBA from University of California at Los Angeles (UCLA).

 

 

John V. Oyler has served as CEO and Director of BeiGene since its founding in 2010. Prior to that, he was Founder & CEO of BioDuro, a 700-person integrated research CRO in Beijing, sold to PPD with attractive returns. He was also previously CEO of Galenea, a Boston biotech started from MIT with funding from Otsuka, Founder and President of Telephia, which was sold to Nielsen, and Co-CEO of Genta, a publicly-traded oncology company that grew to $1.7bn in revenues. John began his career at McKinsey & Company, and holds an MBA from Stanford University and a BS from MIT.

 

 

 

 

 

 

Bruno Delie has more than 20 years of experience in the global pharmaceutical business. Prior to being appointed General Manager of Luye Pharma in Switzerland, he was a board member and executive VP at Ethypharm. There, he was responsible for international development and the company’s transition to a specialty pharma model. Before joining Ethypharm, Bruno Delie acquired wide-ranging experience in corporate and business development as well as international sales and marketing. He has also worked in various licensing and sales management roles for a number of European, American, and Asian companies. Bruno Delie is a graduate of the Pharmaceutical University of Lille and has an MBA from HEC Paris.

 

 


Dr. Ru-Yi He
received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH) of Bethesda, Maryland. He has published more than 20 research papers and abstracts in the field of Internal Medicine and Drug Regulatory Science. He is a licensed, board-certified physician in Internal Medicine. More info...

 

 

 

Nigel Sheail is Head of Mergers & Acquisitions and Business Development & Licensing since September 1st, 2017 and joined Novartis in 2015 as Head of Business Development & Licensing. He is a member of the Pharmaceutical Executive Committee and Financial Leadership Team. Prior to joining Novartis, Nigel was Head of Business Development and Licensing for Bayer Healthcare. He also served as Head of Group M&A at Roche and Head of Licensing for their Pharma division. More info...

 

 

 

 

Martin Rohrbach is Partner and the Sector Head Life Sciences at KPMG Switzerland. He has been with the firm for over 20 years. Martin's comprehensive experience spans from advising multinational pharma companies to upstream supply companies to startups and early phase development companies. Martin is internationally experienced working in different roles in various locations where KPMG is present. He has a proven track record of putting his broad experience to good use at both large multinational corporations as well as local businesses. He is committed to the industry by leading KPMG's Swiss Biotech Initiative and being a member of the international Life Sciences Network. Martins holds a Bachelor's degree in business administration and economics and is a Swiss Certified Auditor.

 

 

Matthias Leuenberger is Country President of Novartis in Switzerland. In this function he serves as Chairman of the Executive Committee of Novartis Switzerland, is responsible for the company’s political relations in Switzerland and represents Novartis in the business associations Interpharma, scienceindustries, economiesuisse and HKBB (Chamber of Trade and Commerce for Basel-Stadt and Baselland). Before joining Novartis, he spent 9 years working for Boston Consulting Group in Zurich and Tokyo. Matthias Leuenberger studied law at the University of Bern, completing his bar exam in 1993 and gaining his doctorate in 1995. He is married and has three children.

 

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland, the company he started in 1999 based on collaboration with the Novartis Venture Fund, which became his first client. Since then he has been involved in over 500 valuations around the globe for investors as well as Biotech, Pharma and Medtech companies. From 2013 to 2015 Patrik built the APAC Office of Venture Valuation in Singapore. Venture Valuation runs Biotechgate, a global Life Sciences database including company/asset profiles, deal information and investors and launched its premier business partnering software HelloPartnering in 2017. Patrik graduated from the Business University of St. Gallen in Finance and completed his Ph.D thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, EPFL. Patrik has experience as a board member of public and private companies and published in a number scientific journals including “Nature Biotechnology”.